There was a role for adjuvant neratinib in high-risk groups of ER+ HER2+ BC patients who completed adjuvant trastuzumab, but the overall recommendation in recent trials suggests the benefit is small, especially when taking into consideration treatment with the combination of pertuzumab and trastuzumab, or with T-DM1 for residual disease, all of which are less toxic and more tolerable than neratinib. Here, ERBB2 is linked to breast cancer.